Clinical Trial Update: Tislelizumab Plus Lenvatinib in Stage III-IV RCC [Phase 2]

View source ↗

Summary

A Phase 2 trial updating tislelizumab plus lenvatinib in advanced kidney cancer is underway; results are currently unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kidney Cancer

Drugs mentioned

• Lenvatinib (lenvatinib)
• Tislelizumab (tislelizumab)

Snippet

Sponsor: Tianjin Medical University Second Hospital | Conditions: Advanced Kidney Cancer | Phase 2 | Status: UNKNOWN